AllSci News
Insilico Medicine and Liquid AI partner on lightweight AI foundation models for drug discovery
Insilico Medicine, a clinical-stage AI-driven drug discovery company headquartered in Hong Kong, and Liquid AI, a Cambridge, Massachusetts-based AI...
Liminatus Pharma raises USD 4m in best-efforts public offering
Cerritos, California-based Liminatus Pharma (NASDAQ: LIMN) announced the pricing of a best-efforts public offering expected to generate approximately USD...
University of Toronto researchers show reengineered long noncoding RNAs reduce inflammation in macrophages and mice
Researchers at the University of Toronto and The Hospital for Sick Children (SickKids) in Toronto, Canada, report that naturally occurring long noncoding...
FDA Approves ACCRUFeR by Shield Therapeutics as First Prescription Oral Iron for Pediatric Iron Deficiency
The US FDA has approved ACCRUFeR (ferric maltol) for the treatment of iron deficiency in children aged 10 years and older, Shield Therapeutics announced on...
Innovent and Lilly's $8.5B Oncology Deal Sparks Global Cancer Research Collaboration
Innovent and Lilly Forge Strategic Alliance to Advance Global Oncology and Immunology Research
Gilgamesh Pharma Raises USD 60M Series A to Advance Neuropsychiatric Drug Pipeline
Gilgamesh Pharma, a clinical-stage neuroscience company headquartered in New York, has closed an oversubscribed USD 60 million Series A financing round to...
Artelo Biosciences raises USD 11m in private placement
Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company based in Solana Beach, California, announced an Artelo $11 million private...
Partner Therapeutics' zenocutuzumab shows continued benefit beyond progression in NRG1 fusion lung cancer
Partner Therapeutics (PTx), a Massachusetts-based biotechnology company, announced new findings from a post hoc analysis of the eNRGy trial evaluating...
Incyte receives CRL for Zynyz in metastatic lung cancer due to manufacturing facility issues
Incyte Corporation disclosed in a SEC filing dated March 6, 2026, that the US Food and Drug Administration issued a Complete Response Letter on February 27,...
Salspera files to raise USD 85m via Nasdaq IPO for oncology biopharmaceutical platform
Salspera, Inc. (proposed Nasdaq: TKVA), a Cambridge, Massachusetts-based clinical-stage biopharmaceutical company, filed a prospectus for an initial public...
Boehringer Ingelheim licenses preclinical immunometabolic program from Sitryx Therapeutics for over USD 500m
Boehringer Ingelheim (Ingelheim am Rhein, Germany) and Sitryx Therapeutics (Oxford, UK) announced on 26 February 2026 that Boehringer has acquired an...
FDA approves GSK's Lynavoy for cholestatic pruritus in primary biliary cholangitis
The US FDA has approved Lynavoy (linerixibat) for the treatment of cholestatic pruritus in adult patients with primary biliary cholangitis, GSK announced on...
Samsung Bioepis, Epis NexLab and G2GBIO partner on long-acting semaglutide using microsphere technology
Samsung Bioepis, Epis NexLab, and G2GBIO Enter Research Collaboration and License Agreement for Long-Acting Semaglutide
Roche halts emugrobart development in spinal muscular atrophy after MANATEE study fails
Roche has discontinued development of emugrobart (GYM329), an investigational anti-myostatin antibody, in spinal muscular atrophy after Part 1 of the Phase...
Pfizer's atirmociclib cuts progression risk by 40% in second-line metastatic breast cancer trial
Pfizer (NYSE: PFE) reported Phase II results for atirmociclib in HR-positive, HER2-negative metastatic breast cancer, with the FOURLIGHT-1 trial meeting its...
The AllSci Brief
Systematic R&D and deal news. Daily.